(()=>{var e={};e.id=859,e.ids=[859],e.modules={846:e=>{"use strict";e.exports=require("next/dist/compiled/next-server/app-page.runtime.prod.js")},1327:(e,i,a)=>{"use strict";a.r(i),a.d(i,{GlobalError:()=>r.a,__next_app__:()=>m,pages:()=>d,routeModule:()=>h,tree:()=>c});var n=a(260),s=a(8203),t=a(5155),r=a.n(t),o=a(7292),l={};for(let e in o)0>["default","tree","pages","GlobalError","__next_app__","routeModule"].indexOf(e)&&(l[e]=()=>o[e]);a.d(i,l);let c={children:["",{children:["team-member-detail",{children:["__PAGE__",{},{page:[()=>Promise.resolve().then(a.bind(a,9827)),"D:\\sandbox\\app\\team-member-detail\\page.js"]}]},{metadata:{icon:[async e=>(await Promise.resolve().then(a.bind(a,6055))).default(e)],apple:[],openGraph:[],twitter:[],manifest:void 0}}]},{layout:[()=>Promise.resolve().then(a.bind(a,9611)),"D:\\sandbox\\app\\layout.tsx"],"not-found":[()=>Promise.resolve().then(a.t.bind(a,9937,23)),"next/dist/client/components/not-found-error"],forbidden:[()=>Promise.resolve().then(a.t.bind(a,9116,23)),"next/dist/client/components/forbidden-error"],unauthorized:[()=>Promise.resolve().then(a.t.bind(a,1485,23)),"next/dist/client/components/unauthorized-error"],metadata:{icon:[async e=>(await Promise.resolve().then(a.bind(a,6055))).default(e)],apple:[],openGraph:[],twitter:[],manifest:void 0}}]}.children,d=["D:\\sandbox\\app\\team-member-detail\\page.js"],m={require:a,loadChunk:()=>Promise.resolve()},h=new n.AppPageRouteModule({definition:{kind:s.RouteKind.APP_PAGE,page:"/team-member-detail/page",pathname:"/team-member-detail",bundlePath:"",filename:"",appPaths:[]},userland:{loaderTree:c}})},1502:(e,i,a)=>{"use strict";a.d(i,{A:()=>h});var n=a(2740);a(6301);var s=a(5271),t=a(3418),r=a(9607),o=a.n(r);let l=({memberName:e})=>(0,n.jsxs)("section",{className:"relative bg-cover bg-center py-6 h-24",style:{backgroundImage:"url('/images/bredcrumb.jpg')"},children:[(0,n.jsx)("div",{className:"relative z-10 mb-1 -mt-3",children:(0,n.jsx)("div",{className:"container mx-auto px-4",children:(0,n.jsxs)("nav",{className:"flex items-center space-x-2 text-sm",children:[(0,n.jsx)(o(),{href:"/",className:"text-white hover:text-yellow-400 underline",children:"Home"}),(0,n.jsx)("span",{className:"text-white",children:(0,n.jsx)("svg",{className:"w-3 h-3",fill:"currentColor",viewBox:"0 0 20 20",children:(0,n.jsx)("path",{fillRule:"evenodd",d:"M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z",clipRule:"evenodd"})})}),(0,n.jsx)(o(),{href:"/our-team",className:"text-white hover:text-yellow-400 underline",children:"Team Members"}),(0,n.jsx)("span",{className:"text-white",children:(0,n.jsx)("svg",{className:"w-3 h-3",fill:"currentColor",viewBox:"0 0 20 20",children:(0,n.jsx)("path",{fillRule:"evenodd",d:"M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z",clipRule:"evenodd"})})}),(0,n.jsx)("span",{className:"text-white",children:e})]})})}),(0,n.jsxs)("div",{className:"relative z-10 text-center -mt-2",children:[(0,n.jsx)("h1",{className:"text-4xl md:text-5xl font-bold text-white mb-2",children:e}),(0,n.jsx)("div",{className:"w-16 h-1 bg-yellow-400 mx-auto"})]})]});var c=a(5635);let d=({memberData:e})=>(0,n.jsx)("div",{className:"lg:sticky lg:top-8",children:(0,n.jsxs)("div",{className:"bg-white rounded-lg shadow-lg overflow-hidden",children:[(0,n.jsx)("div",{className:"relative",children:(0,n.jsx)(c.default,{src:e.image,alt:e.name,width:400,height:500,className:"w-full h-96 object-cover"})}),(0,n.jsx)("div",{className:"p-6",children:(0,n.jsxs)("div",{className:"text-center",children:[(0,n.jsx)("h2",{className:"text-2xl font-bold text-gray-900 mb-2",children:e.name}),(0,n.jsx)("h4",{className:"text-lg text-gray-600 mb-4",children:e.position}),e.linkedinUrl&&(0,n.jsx)(o(),{href:e.linkedinUrl,target:"_blank",rel:"noopener noreferrer",className:"inline-flex items-center justify-center w-12 h-12 bg-blue-600 hover:bg-blue-700 text-white rounded-full transition-colors duration-300",children:(0,n.jsx)("svg",{className:"w-6 h-6",fill:"currentColor",viewBox:"0 0 20 20",children:(0,n.jsx)("path",{fillRule:"evenodd",d:"M16.338 16.338H13.67V12.16c0-.995-.017-2.277-1.387-2.277-1.39 0-1.601 1.086-1.601 2.207v4.248H8.014v-8.59h2.559v1.174h.037c.356-.675 1.227-1.387 2.526-1.387 2.703 0 3.203 1.778 3.203 4.092v4.711zM5.005 6.575a1.548 1.548 0 11-.003-3.096 1.548 1.548 0 01.003 3.096zm-1.337 9.763H6.34v-8.59H3.667v8.59zM17.668 1H2.328C1.595 1 1 1.581 1 2.298v15.403C1 18.418 1.595 19 2.328 19h15.34c.734 0 1.332-.582 1.332-1.299V2.298C19 1.581 18.402 1 17.668 1z",clipRule:"evenodd"})})})]})})]})}),m=({content:e})=>(0,n.jsx)("div",{className:"bg-white rounded-lg shadow-lg p-8",children:(0,n.jsx)("div",{className:"prose prose-lg max-w-none",children:e.map((i,a)=>(0,n.jsxs)("div",{children:[(0,n.jsx)("p",{className:"text-gray-700 leading-relaxed text-lg mb-6",children:i}),a<e.length-1&&(0,n.jsx)("div",{className:"h-5"})]},a))})}),h=({memberData:e})=>(0,n.jsxs)("div",{className:"min-h-screen bg-gray-50",children:[(0,n.jsx)(s.default,{}),(0,n.jsxs)("main",{children:[(0,n.jsx)(l,{memberName:e.name}),(0,n.jsx)("section",{className:"py-12",children:(0,n.jsx)("div",{className:"container mx-auto px-4",children:(0,n.jsxs)("div",{className:"grid grid-cols-1 lg:grid-cols-4 gap-8",children:[(0,n.jsx)("div",{className:"lg:col-span-1",children:(0,n.jsx)(d,{memberData:e})}),(0,n.jsx)("div",{className:"lg:col-span-3",children:(0,n.jsx)(m,{content:e.content})})]})})})]}),(0,n.jsx)(t.A,{})]})},2561:(e,i,a)=>{Promise.resolve().then(a.bind(a,5271)),Promise.resolve().then(a.t.bind(a,9607,23)),Promise.resolve().then(a.t.bind(a,1066,23))},3033:e=>{"use strict";e.exports=require("next/dist/server/app-render/work-unit-async-storage.external.js")},3295:e=>{"use strict";e.exports=require("next/dist/server/app-render/after-task-async-storage.external.js")},3873:e=>{"use strict";e.exports=require("path")},4354:(e,i,a)=>{"use strict";a.d(i,{p:()=>n});let n={drAvanishKumar:{name:"Dr. Avanish Kumar",position:"Promoter",image:"/images/team/DrAvinash.png",linkedinUrl:"https://www.linkedin.com/in/avanish-kumar-phd-a034791b0/",content:["Dr. Avanish Kumar is the visionary leader driving Operifytech Pvt. Ltd., overseeing operations across the entire business cycle - Genomics, Research and Development, Collaborations, Business Development, Sales Operations, and other Corporate functions. He is dedicated to pioneering next-generation, value-based healthcare solutions for the scientific community. With a Ph.D. in Biotechnology and over a decade of experience in the institutional and healthcare sectors, Dr. Kumar seamlessly integrates the scientific and business facets of genomics.","Throughout his distinguished career, Dr. Kumar has held key positions at prestigious institutions. His expertise in NGS assay development, laboratory operations has been pivotal in establishing and managing multiple molecular diagnostic labs. His contributions to the field are well-documented, with numerous publications and review articles in high-impact journals.","Dr. Kumar is a firm believer in the power of strong teams and a culture of compassion and purpose to achieve research excellence. His strategic vision and commitment to innovative solutions place Operifytech at the cutting edge of genomics research and healthcare innovation."]},drGoriparthiRamakrishna:{name:"Dr. Goriparthi Ramakrishna",position:"Lab Head",image:"/images/team/Frame 5.png",linkedinUrl:"https://www.linkedin.com/in/goriparthi-ramakrishna/",content:["Dr. Goriparthi Ramakrishna leads the genomics services lab at Operifytech Pvt. Ltd., driving forward cutting-edge research and maintaining the highest standards of quality management. He brings over 13 years of extensive research experience in genomics and holds Ph.D. from ICAR-NIPB specializing in plant genomics.","Dr. Ramakrishna is a distinguished expert in his field and his accomplished career includes key roles at various renowned labs and institutions, where he led innovative projects in gene expression, transcriptome analysis, and the development of high-quality genome assemblies. Dr. Ramakrishna's expertise covers a wide range of genomic applications, from standardizing DNA/RNA extraction protocols to planning sequencing runs on advanced platforms.","His dedication to advancing functional genomics and his significant contributions to understanding cellular mechanisms and genetic variations have been widely recognized, with numerous publications and review articles in high-impact journals. Dr. Ramakrishna has consistently pushed the boundaries of genomics research, making remarkable strides in plant genomics and bioinformatics. His leadership and technical prowess are invaluable assets to Operify, driving our mission to revolutionize genomics research and applications."]},drDivyankMahajan:{name:"Dr. Divyank Mahajan",position:"Head, Techno-Commercial Strategy",image:"/images/team/Frame 6.png",linkedinUrl:"https://in.linkedin.com/in/divyank-mahajan-phd",content:["At Operify Tech, Dr. Divyank Mahajan heads the Techno-Commercial Strategy, combining his scientific acumen and strategic commercial insights. Dr. Mahajan has a Ph.D. in Cancer Genetics and has served as a Product Manager and Application Scientist in the genomics world, and is uniquely positioned to bridge these worlds of science and business.","Dr. Mahajan's areas of expertise include advanced genomics, particularly next-generation sequencing (NGS), single-cell, and spatial genomics. He focuses on translating complex scientific data into actionable commercial strategies that enable organizations to confidently make clinical development, market access, and commercialization decisions. He is an expert in creating and delivering high-value integrated primary market research (PMR) solutions and secondary research to enable strategic decision making for commercial functions, business units, and C-level stakeholders.","Dr. Mahajan is a renowned scientific rigor and market foresight as a strategic advisor to cross-functional teams. He helps healthcare and genomics organizations understand new opportunities, uncover stakeholder needs, and build data-driven go-to-market strategies. His leadership is defined by commitment to scientific depth, evidence-based planning, and aligning with technical innovation with real-world market impact."]},drMohammedMoquitulHaque:{name:"Dr. Mohammed Moquitul Haque",position:"Lead Scientist - Clinical Genomics",image:"/images/team/Frame 4.png",linkedinUrl:"https://www.linkedin.com/in/moquitul-haque-phd-9a405561/",content:["Dr. Mohammed Moquitul Haque leads the Clinical Genomics division at Operifytech Pvt. Ltd., bringing over a decade of expertise in human genetics, molecular diagnostics, and translational oncology. He holds a Ph.D. in Life Sciences (Cancer Genetics) from Advanced centre for Treatment Research and Education in Cancer – Tata Memorial Centre (ACTREC-TMC) and has led high-impact teams and projects across leading genomics laboratories in India.","Dr. Haque's core expertise lies in the interpretation of somatic variants for solid tumors and hematological malignancies and germline variants for hereditary cancers, rare genetic disorders, using advanced NGS platforms. His experience spans a wide array of technologies, including Exome sequencing, Sanger sequencing, MLPA, RT-PCR. He has played pivotal roles in developing and validating molecular and NGS based assays, optimizing bioinformatics workflows, and enhancing clinical report quality across various tests in different molecular labs.","A recognized leader in oncogenomics, rare disorder genomics, molecular assays and clinical variant curation, Dr. Haque has significantly contributed to precision medicine initiatives and has record of training and mentoring scientific teams. His contributions are marked by publications and a strong commitment to integrating genomics into routine clinical care. At Operifytech Pvt. Ltd., he spearheads the clinical genomics division, advancing the challenging mission to translate genomic data into actionable insights for patient-centric diagnostics and research."]},richaMalhotra:{name:"Richa Malhotra",position:"Business Manager - Clinical Genomic",image:"/images/team/Frame 12.png",linkedinUrl:"https://www.linkedin.com/in/richa-malhotra1/",content:["Richa Malhotra leads product strategy and innovation at Operify Tech, bringing over 12 years of experience in genomics, cancer research, and product management. An alumna of IIM Bangalore with a background in human genetics and bioinformatics, she plays a pivotal role in shaping Operify's multiomics portfolio and advancing our vision in precision medicine.","Richa has successfully launched multiple genomics-based tests and built solutions that are widely adopted across clinical and research settings. Her expertise lies in translating complex scientific advancements into impactful, scalable products—bridging the gap between cutting-edge research and real-world application","With her unique blend of scientific insight and strategic thinking, Richa drives Operify's commitment to delivering high-quality, accessible genomic solutions. Her leadership continues to guide the development of next-generation diagnostics solutions that address the evolving needs of the healthcare and life sciences community."]}}},5214:(e,i,a)=>{Promise.resolve().then(a.bind(a,1584)),Promise.resolve().then(a.t.bind(a,8531,23)),Promise.resolve().then(a.t.bind(a,1902,23))},9121:e=>{"use strict";e.exports=require("next/dist/server/app-render/action-async-storage.external.js")},9294:e=>{"use strict";e.exports=require("next/dist/server/app-render/work-async-storage.external.js")},9551:e=>{"use strict";e.exports=require("url")},9827:(e,i,a)=>{"use strict";a.r(i),a.d(i,{default:()=>r});var n=a(2740);a(6301);var s=a(1502),t=a(4354);function r(){let e=t.p.drAvanishKumar;return(0,n.jsx)(s.A,{memberData:e})}}};var i=require("../../webpack-runtime.js");i.C(e);var a=e=>i(i.s=e),n=i.X(0,[638,693,217,362],()=>a(1327));module.exports=n})();